| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.9 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | Zebularine | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |